Dianthus Therapeutics, Inc. (NASDAQ:DNTH) Short Interest Update

Dianthus Therapeutics, Inc. (NASDAQ:DNTH) saw a significant increase in short interest in the month of April. As of April 30th, there was short interest totalling 2,150,000 shares, an increase of 12.6% from the April 15th total of 1,910,000 shares. Based on an average trading volume of 170,300 shares, the days-to-cover ratio is presently 12.6 days. Approximately 10.0% of the company’s stock are sold short.

Institutional Investors Weigh In On Dianthus Therapeutics

A number of institutional investors have recently added to or reduced their stakes in the stock. Tower Research Capital LLC TRC acquired a new stake in shares of Dianthus Therapeutics in the fourth quarter valued at about $25,000. Citigroup Inc. purchased a new position in shares of Dianthus Therapeutics in the third quarter valued at approximately $53,000. Acadian Asset Management LLC purchased a new position in Dianthus Therapeutics in the 3rd quarter valued at $303,000. Laurion Capital Management LP acquired a new stake in Dianthus Therapeutics during the 3rd quarter worth $497,000. Finally, Hussman Strategic Advisors Inc. acquired a new stake in shares of Dianthus Therapeutics in the first quarter valued at about $630,000. Institutional investors and hedge funds own 47.53% of the company’s stock.

Analysts Set New Price Targets

Several equities analysts recently issued reports on DNTH shares. Wedbush lifted their price objective on shares of Dianthus Therapeutics from $33.00 to $38.00 and gave the company an “outperform” rating in a report on Friday, May 10th. Raymond James raised their target price on Dianthus Therapeutics from $34.00 to $51.00 and gave the stock an “outperform” rating in a research note on Thursday, April 18th. Stifel Nicolaus began coverage on Dianthus Therapeutics in a research report on Thursday, February 15th. They issued a “buy” rating and a $44.00 target price on the stock. HC Wainwright started coverage on shares of Dianthus Therapeutics in a report on Thursday. They set a “buy” rating and a $40.00 target price for the company. Finally, Jefferies Financial Group upped their price target on shares of Dianthus Therapeutics from $22.00 to $39.00 and gave the company a “buy” rating in a report on Friday, March 22nd. Six equities research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, Dianthus Therapeutics has an average rating of “Buy” and a consensus target price of $42.83.

Dianthus Therapeutics Price Performance

DNTH stock traded down $0.49 during midday trading on Friday, hitting $25.76. 10,466 shares of the stock traded hands, compared to its average volume of 139,820. The stock’s fifty day simple moving average is $25.62 and its 200-day simple moving average is $18.78. The firm has a market cap of $756.06 million, a P/E ratio of -4.50 and a beta of 1.77. Dianthus Therapeutics has a 1-year low of $6.58 and a 1-year high of $33.77.

Dianthus Therapeutics (NASDAQ:DNTH) last announced its quarterly earnings results on Thursday, March 21st. The company reported ($0.71) earnings per share for the quarter, beating the consensus estimate of ($1.11) by $0.40. The business had revenue of $0.46 million during the quarter, compared to analysts’ expectations of $0.73 million. On average, research analysts predict that Dianthus Therapeutics will post -2.29 earnings per share for the current year.

About Dianthus Therapeutics

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy.